SIHUAN PHARM (00460.HK): Bireociclib Adds First-Line NRDL Cover

On 16 November 2026, SIHUAN PHARM (00460.HK) said a new first-line breast cancer indication for Bireociclib entered China's 2026 NRDL, effective 1 January 2027.

NewTimeSpace News: On 16 November 2026, Sihuan Pharmaceutical Holdings Group Ltd. (stock code: 0460) announced that a new indication of Bireociclib Tablets, an innovative drug independently developed by its non wholly-owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd. (stock code: 02575.HK), in combination with aromatase inhibitors (AIs) for the first-line treatment of HR+/HER2- advanced breast cancer, has been included in the National Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance (2026), which takes effect on 1 January 2027. All three indications of Bireociclib approved in Mainland China are now on the NRDL.

Bireociclib (brand name: Xuanyuening) is China's first approved CDK2/4/6 inhibitor, with a multi-target synergistic mechanism that potently inhibits tumour cell proliferation while significantly reducing the haematological toxicity commonly seen with conventional CDK4/6 inhibitors. Its three approved indications are: in combination with AIs for initial endocrine therapy in adults with HR+/HER2- locally advanced or metastatic breast cancer; in combination with fulvestrant for patients whose disease progressed after prior endocrine therapy; and as monotherapy for patients whose disease progressed after at least two endocrine therapies and one chemotherapy in the metastatic setting. With the new indication, the drug achieves full NRDL reimbursement coverage across first-, second- and later-line treatment of HR+/HER2- advanced breast cancer.

The Company said the inclusion will further expand the potential patient population, help accelerate hospital access and clinical use, advance commercialisation and consolidate Xuanzhu Biopharm's and the Group's competitive position in HR+/HER2- advanced breast cancer, while easing patients' financial burden and improving access to the innovative drug.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.